Organic compounds -- part of the class 532-570 series – Organic compounds – Carboxylic acid esters
Reexamination Certificate
2011-08-02
2011-08-02
Sullivan, Daniel M (Department: 1621)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carboxylic acid esters
Reexamination Certificate
active
07989654
ABSTRACT:
The invention relates to a compound of general formula (I) wherein A represents deuterium or hydrogen, R represents a group selected from C1-6alkyl, C3-10cycloalkyl or phenyl, which can be substituted by C1-3 alkoxy, fluorine, chlorine, bromine, iodine, nitro, amino, hydroxyl, oxo, mercapto or deuterium. The C atom marked with a * (star) can be present in an (R) configuration, in an (S)-configuration or a mixture thereof. The invention is characterized in that the above-mentioned compounds are free bases with a degree of purity of more than 97 wt %. The invention also relates to a method for the production of highly pure compounds of general formula (I) and to the use thereof in the production of medicaments.
REFERENCES:
patent: 2556636 (1951-06-01), Sperber et al.
patent: 2567245 (1951-09-01), Sperber et al.
patent: 2676964 (1954-04-01), Sperber et al.
patent: 3261841 (1966-07-01), Zenitz
patent: 3446901 (1969-05-01), Macclesfield
patent: 4675009 (1987-06-01), Hymes et al.
patent: 4988730 (1991-01-01), Korbonits et al.
patent: 5271940 (1993-12-01), Cleary et al.
patent: 5382600 (1995-01-01), Jonsson et al.
patent: 5559269 (1996-09-01), Johansson et al.
patent: 5922914 (1999-07-01), Gage et al.
patent: 6310248 (2001-10-01), Andersson et al.
patent: 6517864 (2003-02-01), Jacobsen et al.
patent: 6566537 (2003-05-01), Andersson et al.
patent: 6630162 (2003-10-01), Nilvebrant et al.
patent: 6689916 (2004-02-01), Andersson et al.
patent: 6713464 (2004-03-01), Meese et al.
patent: 6770295 (2004-08-01), Kreilgard et al.
patent: 6783769 (2004-08-01), Arth et al.
patent: 6809214 (2004-10-01), Meese
patent: 6809225 (2004-10-01), Donsbach et al.
patent: 6858650 (2005-02-01), Meese
patent: 6890920 (2005-05-01), Richards et al.
patent: 6911217 (2005-06-01), Gren et al.
patent: 6936718 (2005-08-01), Chen et al.
patent: 7008637 (2006-03-01), Jacobsen et al.
patent: 7230030 (2007-06-01), Meese et al.
patent: 7670621 (2010-03-01), Breitenbach et al.
patent: 2003/0152624 (2003-08-01), Aldrich et al.
patent: 2004/0064821 (2004-04-01), Rousselle
patent: 2005/0004223 (2005-01-01), Slatter et al.
patent: 830193 (1952-02-01), None
patent: 766207 (1952-12-01), None
patent: 925468 (1955-03-01), None
patent: 1216318 (1966-05-01), None
patent: 325571 (1989-07-01), None
patent: 667852 (1995-08-01), None
patent: 948321 (1997-12-01), None
patent: 831799 (1998-04-01), None
patent: 872233 (1998-10-01), None
patent: 957073 (1999-11-01), None
patent: 1019358 (2000-07-01), None
patent: 1128819 (2001-09-01), None
patent: 1 077 912 (2002-07-01), None
patent: 624117 (1949-05-01), None
patent: 627139 (1949-07-01), None
patent: 685696 (1953-01-01), None
patent: 689835 (1953-04-01), None
patent: 690274 (1953-04-01), None
patent: 692931 (1953-06-01), None
patent: 1025041 (1966-04-01), None
patent: 1169944 (1969-11-01), None
patent: 1169945 (1969-11-01), None
patent: 2199525 (2003-02-01), None
patent: 93/23025 (1993-11-01), None
patent: 94/11337 (1994-05-01), None
patent: WO-94/11337 (1994-05-01), None
patent: 96/12477 (1996-05-01), None
patent: 98/03067 (1998-01-01), None
patent: 98/43942 (1998-10-01), None
patent: 98/56359 (1998-12-01), None
patent: 99/58478 (1999-11-01), None
patent: WO-99/58478 (1999-11-01), None
patent: WO 9958478 (1999-11-01), None
patent: 00/12069 (2000-03-01), None
patent: WO-00/12070 (2000-03-01), None
patent: 00/27364 (2000-05-01), None
patent: 01/34139 (2001-05-01), None
patent: WO-01/35957 (2001-05-01), None
patent: 02/11702 (2002-02-01), None
patent: 02/089773 (2002-11-01), None
patent: 03/002059 (2003-01-01), None
patent: 03/007918 (2003-01-01), None
patent: 03/020241 (2003-03-01), None
patent: 03/021271 (2003-03-01), None
patent: 03/026564 (2003-04-01), None
patent: 03/035599 (2003-05-01), None
patent: 03/039464 (2003-05-01), None
patent: 03/063834 (2003-08-01), None
patent: 03/099268 (2003-12-01), None
patent: 03/103637 (2003-12-01), None
patent: 03/106421 (2003-12-01), None
patent: 2004/019892 (2004-03-01), None
patent: WO-2004/089346 (2004-10-01), None
Berge et al. Journal of Pharmaceutical Sciences, 1977, vol. 66, pp. 1-19.
Approval letter for tolterodine tartrate, Mar. 25, 1998.
Abrams et al., “Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder,” 1998, Br. J. Urol. 81:801-810.
Abstracts from the 26th Annual Meeting of the International Incontinence Society, Aug. 27-30, 1996, Gillberg et al., abstract 33, Neurology and Urodynamics 15:308-309.
Anderson et al., “Once daily controlled versus immediate release oxybutynin chloride for urge urinary incontinence,” 1999, J. Urol. 161:1809-1812.
Andersson et al., “Pharmacological treatment of urinary incontinence,” in Abrams P., Khoury S., Wein A. (Eds), Incontinence, 2nd International Consultation on Incontinence, Plymouth, Plymbridge Distributors Ltd, UK, Plymouth, 2002, pp. 479-511.
Andersson, “Antimuscarinics for treatment of overactive bladder,” 2004, Lancet Neurol. 3:46-53.
Andersson & Hedlund, “Pharmacological perspective on the physiology of the lower urinay tract,” 2002, Urology 60 (Suppl. 5A):13-20.
Andersson & Wein, “Pharmacology of the lower urinary tract: basis for current and future treatments of urinary incontinence,” 2004, Pharmacol. Rev. 56:581-631.
Appell et al., “Prospective randomized controlled trial of extended release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT study,” 2001, Mayo Clinic Proceedings 76:358-363.
Breidenbach et al., “Pharmacodynamic profiling of the novel antimuscarinic drug fesoterodine on rat bladder,” 2002, Proceedings of the International Continence Society, 32:449.
Brynne et al., Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine, 1998, Clin. Pharmacol. Thera. 63:529-539.
Brynne et al., “Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine, and omeprazole,” 1999, Br. J. Clin. Pharmacol. 47:145-150.
Brynne et al., “Fluoxetine inhibits the metabolism of tolterodine—pharmacokinetic implications and proposed clinical relevance,” 1999, Br. J. Clin. Pharmacol. 48:553-563.
Brynne et al., “Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity,” 1999, Br. J. Clin. Pharmacol. 48:564-572.
Cawello et al., “Multiple dose pharmacokinetics of fesoterodine in human subjects,” 2002, Nauyn-Schmiedeberg's Arch. Pharmacol. 365 (Suppl. 1):428, 2002.
Chancellor et al., “A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate,” 2001, Clinical Therapeutics 23:753-760.
Chapple & Udo, “Delay to maximum effect in overactive bladder patients treated with oxybutynin or tolterodine,” 2000, European Urology 37(Suppl. 2):84, abstract 335 from the XVth Congress of the European Association of Urology, Brussels, Belgium, Apr. 12-15, 2000.
Chapple et al., “Fesoterodine a new effective and well-tolerated antimuscarinic for the treatment of urgency-frequency syndrome: results of a Phase II controlled study,” 2004, Proceedings of the International Continence Society, 34:142.
Clemett & Jarvis, “Tolterodine: a review of its use in the treatment of overactive bladder,” 2001, Drugs & Aging 18:277-304.
Cole, “Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: A safety update,” 2004, Drugs of the Future 29:715-720.
Committee for Proprietary Medicinal Products, “The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products,” CPMP/986/96, Dec. 17, 1997.
Detrol® package insert, Pharmacia & Upjohn Co., Apr. 2004.
Diokno et al., “Tolterodine (Detrol®) improves incontinence and nocturia in urological based study,” Apr. 1999, J. Urol. 161 (4 Suppl):256, abstract 987.
Ekstr
Breitenbach Armin
Drews Roland
Meese Claus
Wolff Hans-Michael
Kenyon & Kenyon LLP
Sullivan Daniel M
UCB Pharma GmbH
Valenrod Yevegeny
LandOfFree
High purity bases of 3,3-diphenylpropylamino monoesters does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with High purity bases of 3,3-diphenylpropylamino monoesters, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High purity bases of 3,3-diphenylpropylamino monoesters will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2774924